MBRX – moleculin biotech, inc. (US:NASDAQ)

DELAYED
$ usd
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
1D
5D
1M
3M
YTD
1Y
3Y
1 Day MBRX SPY QQQ SPX
Date
Time
Symbol
Company Name
Action
%Chg
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions?
The answers are right here.
Stock Stats
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Top News Gainers
3/19 WPD PHARMACEUTICALS’ WP1122 DRUG TO BE TESTED ON A RANGE OF VIRUSES INCLUDING CORONAVIRUS 41.2%
2/5 WPD Pharmaceuticals’ Annamycin Drug Received FDA Approval of Fast Track Designation 18.0%
3/17 Moleculin Signs Agreement with UTMB to Test WP1122 on a Range of Viruses, Including Coronavirus 15.6%
4/13 WPD Pharmaceuticals to Resume Trading on Monday, April 13, 2020 [Canadian Business Journal (Canada)] 13.3%
3/23 Form S-3/A Moleculin Biotech, Inc. 9.6%
4/14 Moleculin Announces Investor Conference Call to Discuss COVID-19 Potential for Drug Candidate 9.4%
10/22 Moleculin Increases Annamycin Production Due to Positive Clinical Trial Activity and Expanded Potential Indications 8.6%
8/16 Q2/2019 6/30/2019 EPS -0.030 ZacksConsensus -0.090 ActVsEst 0.060 - Beat 8.5%
3/4 Form 8-K Moleculin Biotech, Inc. For: Mar 04 7.0%
11/12 Form 8-K Moleculin Biotech, Inc. For: Nov 12 5.9%
Top News Decliners
3/19 WPD PHARMACEUTICALS’ WP1122 DRUG TO BE TESTED ON A RANGE OF VIRUSES INCLUDING CORONAVIRUS [Canadian Business Journal (Canada)] -50.0%
3/17 Form 8-K Moleculin Biotech, Inc. For: Mar 16 -42.2%
3/16 Form 8-K Moleculin Biotech, Inc. For: Mar 13 -25.9%
2/5 WPD Pharmaceuticals’ Annamycin Drug Received FDA Approval of Fast Track Designation [Canadian Business Journal (Canada)] -21.6%
3/20 Moleculin Announces Patent Filing to Cover New Coronavirus Drug Candidate -20.0%
2/6 Moleculin Biotech Inc (NASDAQ: MBRX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -17.3%
4/2 Moleculin Announces Additional Positive Safety Data in EU AML Trial -15.0%
8/6 Moleculin Announces Breakthrough Discovery: WP1066 Potentially Capable of Immune Reprogramming in Glioblastoma Animal Models -15.0%
2/3 Form 8-K Moleculin Biotech, Inc. For: Feb 03 -14.8%
2/27 WPD Pharmaceuticals’ Annamycin Received Positive Interim Results From Phase 1/2 Clinical Studies in Acute Myeloid Leukemia [Canadian Business Journal (Canada)] -13.5%

Don’t Miss Out On The Next BIG Stock Move

Thanks for submitting the form.
MBRX – moleculin biotech, inc. (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
MBRX
SPY
QQQ
SPX
MBRX – moleculin biotech, inc. (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
MBRX SPY QQQ SPX
Stock Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Stock Stats
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
News
2/18
08:20 am
mbrx
Medium
Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)
2/17
08:35 am
mbrx
Low
Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin
2/13
08:32 am
mbrx
Medium
Moleculin Launches CEO Corner Platform to Share Strategic Insights
2/5
09:15 am
mbrx
Medium
Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
1/13
09:02 am
mbrx
Medium
Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects [Yahoo! Finance]
1/13
08:55 am
mbrx
Medium
Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects 
1/12
08:55 am
mbrx
Low
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs [Yahoo! Finance]
1/12
08:36 am
mbrx
Low
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs
12/17
08:31 am
mbrx
High
Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions? The answers are right here.
12/15
02:08 pm
Reiterates
Buy
Buy
Roth Capital
Medium
-3.5%
12/15
02:08 pm
Reiterates
Buy
Buy
Roth Capital
Medium
-3.5%
12/11
07:20 am
Reiterates
Buy
Buy
HC Wainwright
Low
-2.9%
2/18
04:32 pm
mbrx
Low
Form 8-K Moleculin Biotech, Inc. For: Feb 18
2/18
08:20 am
mbrx
Low
Form 8-K Moleculin Biotech, Inc. For: Feb 18
2/17
08:35 am
mbrx
Medium
Form 8-K Moleculin Biotech, Inc. For: Feb 17
2/5
11:55 am
mbrx
Medium
Form 8-K Moleculin Biotech, Inc. For: Feb 05
1/20
08:01 am
mbrx
Medium
Form 8-K Moleculin Biotech, Inc. For: Jan 20
1/13
08:55 am
mbrx
Low
Form 8-K Moleculin Biotech, Inc. For: Jan 13
1/12
08:36 am
mbrx
Medium
Form 8-K Moleculin Biotech, Inc. For: Jan 12
1/7
08:30 am
mbrx
Medium
Form 8-K Moleculin Biotech, Inc. For: Jan 07
1/7
06:02 am
mbrx
Low
Form EFFECT Moleculin Biotech, Inc.
Show more
Top News Gainers
3/19 WPD PHARMACEUTICALS’ WP1122 DRUG TO BE TESTED ON A RANGE OF VIRUSES INCLUDING CORONAVIRUS 41.2%
2/5 WPD Pharmaceuticals’ Annamycin Drug Received FDA Approval of Fast Track Designation 18.0%
3/17 Moleculin Signs Agreement with UTMB to Test WP1122 on a Range of Viruses, Including Coronavirus 15.6%
4/13 WPD Pharmaceuticals to Resume Trading on Monday, April 13, 2020 [Canadian Business Journal (Canada)] 13.3%
3/23 Form S-3/A Moleculin Biotech, Inc. 9.6%
4/14 Moleculin Announces Investor Conference Call to Discuss COVID-19 Potential for Drug Candidate 9.4%
10/22 Moleculin Increases Annamycin Production Due to Positive Clinical Trial Activity and Expanded Potential Indications 8.6%
8/16 Q2/2019 6/30/2019 EPS -0.030 ZacksConsensus -0.090 ActVsEst 0.060 - Beat 8.5%
3/4 Form 8-K Moleculin Biotech, Inc. For: Mar 04 7.0%
11/12 Form 8-K Moleculin Biotech, Inc. For: Nov 12 5.9%
Top News Decliners
3/19 WPD PHARMACEUTICALS’ WP1122 DRUG TO BE TESTED ON A RANGE OF VIRUSES INCLUDING CORONAVIRUS [Canadian Business Journal (Canada)] -50.0%
3/17 Form 8-K Moleculin Biotech, Inc. For: Mar 16 -42.2%
3/16 Form 8-K Moleculin Biotech, Inc. For: Mar 13 -25.9%
2/5 WPD Pharmaceuticals’ Annamycin Drug Received FDA Approval of Fast Track Designation [Canadian Business Journal (Canada)] -21.6%
3/20 Moleculin Announces Patent Filing to Cover New Coronavirus Drug Candidate -20.0%
2/6 Moleculin Biotech Inc (NASDAQ: MBRX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -17.3%
4/2 Moleculin Announces Additional Positive Safety Data in EU AML Trial -15.0%
8/6 Moleculin Announces Breakthrough Discovery: WP1066 Potentially Capable of Immune Reprogramming in Glioblastoma Animal Models -15.0%
2/3 Form 8-K Moleculin Biotech, Inc. For: Feb 03 -14.8%
2/27 WPD Pharmaceuticals’ Annamycin Received Positive Interim Results From Phase 1/2 Clinical Studies in Acute Myeloid Leukemia [Canadian Business Journal (Canada)] -13.5%